Journal Title：Frontiers In Bioengineering And Biotechnology

The translation of new discoveries in medicine to clinical routine has never been easy. During the second half of the last century, thanks to the progress in chemistry, biochemistry and pharmacology, we have seen the development and the application of a large number of drugs and devices aimed at the treatment of symptoms, blocking unwanted pathways and, in the case of infectious diseases, fighting the micro-organisms responsible. However, we are facing, today, a dramatic change in the therapeutic approach to pathologies and diseases. Indeed, the challenge of the present and the next decade is to fully restore the physiological status of the diseased organism and to completely regenerate tissue and organs when they are so seriously affected that treatments cannot be limited to the repression of symptoms or to the repair of damage. This is being made possible thanks to the major developments made in basic cell and molecular biology, including stem cell science, growth factor delivery, gene isolation and transfection, the advances in bioengineering and nanotechnology, including development of new biomaterials, biofabrication technologies and use of bioreactors, and the big improvements in diagnostic tools and imaging of cells, tissues and organs.

In today`s world, an enhancement of communication between multidisciplinary experts, together with the promotion of joint projects and close collaborations among scientists, engineers, industry people, regulatory agencies and physicians are absolute requirements for the success of any attempt to develop and clinically apply a new biological therapy or an innovative device involving the collective use of biomaterials, cells and/or bioactive molecules. “Frontiers in Bioengineering and Biotechnology” aspires to be a forum for all people involved in the process by bridging the gap too often existing between a discovery in the basic sciences and its clinical application.

將醫學上的新發現轉化為臨床常規從來都不是一件容易的事。在上個世紀下半葉，由于化學、生物化學和藥理學的進步，我們看到了大量藥物和設備的開發和應用，這些藥物和設備旨在治療癥狀、阻斷不必要的途徑，并在傳染病的情況下對抗導致疾病的微生物。然而，今天，我們正面臨著病理和疾病治療方法的巨大變化。事實上，現在和未來十年的挑戰是完全恢復患病生物體的生理狀態，并在組織和器官受到嚴重影響以至于治療不能局限于抑制癥狀或修復損傷時完全再生組織和器官。這得益于基礎細胞和分子生物學的重大發展，包括干細胞科學、生長因子傳遞、基因分離和轉染，生物工程和納米技術的進步，包括新生物材料的開發、生物制造技術和生物反應器的使用，以及診斷工具和細胞、組織和器官成像的巨大改進。

在當今世界，加強多學科專家之間的交流，促進聯合項目以及科學家、工程師、行業人士、監管機構和醫生之間的密切合作，是成功開發和臨床應用新生物療法或創新設備（涉及生物材料、細胞和/或生物活性分子的集體使用）的絕對要求。“生物工程和生物技術前沿”希望成為參與這一過程的所有人的一個論壇，彌合基礎科學發現與其臨床應用之間經常存在的差距。

Frontiers In Bioengineering And Biotechnology創刊于2013年，由Frontiers Media S.A.出版商出版，收稿方向涵蓋Chemical Engineering - Bioengineering全領域，此刊是中等級別的SCI期刊，所以過審相對來講不是特別難，但是該刊專業認可度不錯，仍然是一本值得選擇的SCI期刊 。平均審稿速度 12 Weeks ，影響因子指數4.3，該期刊近期沒有被列入國際期刊預警名單，廣大學者值得一試。